One of the first examples of a combinatory therapeutic strategy demonstrated additive benefit was treatment of SMA mice with a small-molecule inducer of SMN2 expression (D156844) alongside a myoprotectant (follistatin) (133). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.